Clinical responses and persistent V600E blood cells in children with LCH treated with MAPK pathway inhibition.
作者信息
Eckstein Olive S, Visser Johannes, Rodriguez-Galindo Carlos, Allen Carl E
机构信息
Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Houston, TX.
Division of Pediatric Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX.
出版信息
Blood. 2019 Apr 11;133(15):1691-1694. doi: 10.1182/blood-2018-10-878363. Epub 2019 Feb 4.
Abstract
摘要
相似文献
1
Clinical responses and persistent V600E blood cells in children with LCH treated with MAPK pathway inhibition.采用丝裂原活化蛋白激酶（MAPK）信号通路抑制治疗的朗格汉斯细胞组织细胞增多症（LCH）患儿的临床反应及持续性V600E血细胞
Blood. 2019 Apr 11;133(15):1691-1694. doi: 10.1182/blood-2018-10-878363. Epub 2019 Feb 4.
2
[BRAF-V600E mutation and its clinical significance in children with Langerhans cell histiocytosis].[BRAF-V600E突变及其在朗格汉斯细胞组织细胞增多症患儿中的临床意义]
Zhongguo Dang Dai Er Ke Za Zhi. 2018 Apr;20(4):290-294. doi: 10.7499/j.issn.1008-8830.2018.04.007.
3
Association between clinicopathologic characteristics and BRAF expression in Chinese patients with Langerhans cell histiocytosis.中国朗格汉斯细胞组织细胞增生症患者临床病理特征与 BRAF 表达的相关性。
Thorac Cancer. 2019 Oct;10(10):1984-1992. doi: 10.1111/1759-7714.13179. Epub 2019 Aug 23.
4
Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.95 例儿童朗格汉斯细胞组织细胞增生症的临床和预后特征：2013 年至 2020 年单中心经验。
Ann Med. 2021 Dec;53(1):1537-1546. doi: 10.1080/07853890.2021.1966085.
5
V600E Mutation: A Significant Biomarker for Prediction of Disease Relapse in Pediatric Langerhans Cell Histiocytosis.V600E突变：小儿朗格汉斯细胞组织细胞增多症疾病复发预测的重要生物标志物。
Pediatr Dev Pathol. 2019 Oct;22(5):449-455. doi: 10.1177/1093526619847859. Epub 2019 May 9.
6
Circulating cell-free BRAF as a biomarker in children with Langerhans cell histiocytosis.循环无细胞 BRAF 作为朗格汉斯细胞组织细胞增生症患儿的生物标志物。
Br J Haematol. 2017 Aug;178(3):457-467. doi: 10.1111/bjh.14695. Epub 2017 Apr 25.
7
Genetic landscape of adult Langerhans cell histiocytosis with lung involvement.伴有肺部受累的成人朗格汉斯细胞组织细胞增多症的基因图谱。
Eur Respir J. 2020 Feb 27;55(2). doi: 10.1183/13993003.01190-2019. Print 2020 Feb.
8
Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.朗格汉斯细胞组织细胞增生症：一种由 Ras-ERK 通路突变驱动的肿瘤性疾病。
J Am Acad Dermatol. 2018 Mar;78(3):579-590.e4. doi: 10.1016/j.jaad.2017.09.022. Epub 2017 Oct 26.
9
Co-existence of BRAF V600E-mutated malignant melanoma and BRAF V600E-mutated Langerhans cell histiocytosis: A case report.BRAF V600E 突变型恶性黑色素瘤和 BRAF V600E 突变型朗格汉斯细胞组织细胞增生症共存：病例报告。
J Cutan Pathol. 2022 Apr;49(4):393-398. doi: 10.1111/cup.14171. Epub 2021 Nov 28.
10
BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.BRAF突变与高危朗格汉斯细胞组织细胞增多症相关，并与一线治疗耐药性增加有关。
J Clin Oncol. 2016 Sep 1;34(25):3023-30. doi: 10.1200/JCO.2015.65.9508. Epub 2016 Jul 5.
引用本文的文献
1
Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium.荷兰和比利时组织细胞肿瘤患者靶向治疗的真实世界经验。
Blood Neoplasia. 2024 Jun 10;1(3):100023. doi: 10.1016/j.bneo.2024.100023. eCollection 2024 Sep.
2
BRAFV600E induces key features of LCH in iPSCs with cell type-specific phenotypes and drug responses.BRAFV600E在具有细胞类型特异性表型和药物反应的诱导多能干细胞中诱导朗格汉斯细胞组织细胞增生症的关键特征。
Blood. 2025 Feb 20;145(8):850-865. doi: 10.1182/blood.2024026066.
3
Targeted Therapy With Vemurafenib in Brazilian Children With Refractory Langerhans Cell Histiocytosis: Two Case Reports and Review of Literature.维莫非尼靶向治疗巴西难治性朗格汉斯细胞组织细胞增生症患儿：两例病例报告及文献复习。
Cancer Rep (Hoboken). 2024 Aug;7(8):e2142. doi: 10.1002/cnr2.2142.
4
Orbital histiocytosis; From A to Z.眼眶组织细胞增生症；从 A 到 Z。
Int Ophthalmol. 2024 Jun 20;44(1):236. doi: 10.1007/s10792-024-03179-6.
5
Langerhans cell histiocytosis: NACHO update on progress, chaos, and opportunity on the path to rational cures.朗格汉斯细胞组织细胞增生症：NACHO 对进展、混乱和理性治疗之路的机会的更新。
Cancer. 2024 Jul 15;130(14):2416-2439. doi: 10.1002/cncr.35301. Epub 2024 Apr 30.
6
Vemurafenib combined with chemotherapy achieved sustained remission in pediatric LCH: a multi-center observational study.维莫非尼联合化疗使儿科 LCH 获得持久缓解：一项多中心观察性研究。
J Cancer Res Clin Oncol. 2024 Jan 17;150(1):12. doi: 10.1007/s00432-023-05551-y.
7
Circulating senescent myeloid cells infiltrate the brain and cause neurodegeneration in histiocytic disorders.循环衰老髓样细胞浸润大脑并在组织细胞疾病中导致神经退行性变。
Immunity. 2023 Dec 12;56(12):2790-2802.e6. doi: 10.1016/j.immuni.2023.11.011.
8
Langerhans cell histiocytosis: promises and caveats of targeted therapies in high-risk and CNS disease.朗格汉斯细胞组织细胞增生症：高危和中枢神经系统疾病靶向治疗的前景与警示。
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):386-395. doi: 10.1182/hematology.2023000439.
9
Langerhans cell histiocytosis: current advances in molecular pathogenesis.朗格汉斯细胞组织细胞增生症：分子发病机制的最新进展。
Front Immunol. 2023 Oct 26;14:1275085. doi: 10.3389/fimmu.2023.1275085. eCollection 2023.
10
Somatic ARAF mutations in pediatric Langerhans cell histiocytosis: clinicopathologic, genetic and functional profiling.儿童朗格汉斯细胞组织细胞增生症中的体细胞 ARAF 突变：临床病理、遗传和功能分析。
Clin Exp Med. 2023 Dec;23(8):5269-5279. doi: 10.1007/s10238-023-01134-w. Epub 2023 Aug 12.
本文引用的文献
1
Langerhans-Cell Histiocytosis.朗格汉斯细胞组织细胞增多症
N Engl J Med. 2018 Aug 30;379(9):856-868. doi: 10.1056/NEJMra1607548.
2
Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosis.患者朗格汉斯细胞组织细胞增生症中一种新型 MAP2K1 突变相关的临床耐药性。
Pediatr Blood Cancer. 2018 Sep;65(9):e27237. doi: 10.1002/pbc.27237. Epub 2018 May 16.
3
CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions.中枢神经系统朗格汉斯细胞组织细胞增生症：LCH 相关神经退行性变和肿块病变的常见造血起源。
Cancer. 2018 Jun 15;124(12):2607-2620. doi: 10.1002/cncr.31348. Epub 2018 Apr 6.
4
Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties.等位基因特异性激活 MEK1 突变体的机制决定了它们的特性。
Cancer Discov. 2018 May;8(5):648-661. doi: 10.1158/2159-8290.CD-17-1452. Epub 2018 Feb 26.
5
Targeted inhibition of the MAPK pathway: emerging salvage option for progressive life-threatening multisystem LCH.丝裂原活化蛋白激酶（MAPK）通路的靶向抑制：进展性危及生命的多系统朗格汉斯细胞组织细胞增多症新出现的挽救治疗选择
Blood Adv. 2017 Feb 2;1(6):352-356. doi: 10.1182/bloodadvances.2016003533. eCollection 2017 Feb 14.
6
RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions.RAF/MEK/细胞外信号相关激酶通路抑制树突状细胞迁移，并将树突状细胞困在朗格汉斯细胞组织细胞增生症病变中。
J Exp Med. 2018 Jan 2;215(1):319-336. doi: 10.1084/jem.20161881. Epub 2017 Dec 20.
7
Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.维莫非尼治疗 BRAF V600 突变型 Erdheim-Chester 病和朗格汉斯细胞组织细胞增生症：来自组织学独立、开放标签 VE-BASKET 研究的数据分析。
JAMA Oncol. 2018 Mar 1;4(3):384-388. doi: 10.1001/jamaoncol.2017.5029.
8
Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas.伴有中枢神经系统异常的朗格汉斯细胞组织细胞增多症患者的评估与治疗：当前观点与新展望
Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26784. Epub 2017 Sep 25.
9
A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease.红系髓系祖细胞中的体细胞突变会引发神经退行性疾病。
Nature. 2017 Sep 21;549(7672):389-393. doi: 10.1038/nature23672. Epub 2017 Aug 30.
10
Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study).针对54例 Erdheim-Chester病患者的靶向治疗，包括中断治疗后的随访（LOVE研究）。
Blood. 2017 Sep 14;130(11):1377-1380. doi: 10.1182/blood-2017-03-771873. Epub 2017 Jun 30.
Zotero 插件